EUCTR2005-003944-68-DE进行中（未招募）1 期
A Phase II Study of Lapatinib for Brain Metastases in Subjectswith ErbB2-Positive Breast Cancer Following Trastuzumab basedSystemic Therapy and Cranial Radiotherapy
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2;
- •Subjects must have histologically or cytologically confirmed invasive breast cancer,
- •with Stage IV disease;
- •ErbB2 overexpressing breast cancer, defined as 3+ staining by
- •immunohistochemistry (IHC), or 2+ staining by IHC in conjunction with ErbB 2 gene amplification by FISH, or ErbB 2 gene amplification by FISH alone (in subjects whose tumor blocks were not assessed by IHC). Subjects with tumors that are 2+ by IHC but negative by FISH assay are ineligible;
- •At least one measurable lesion in the brain, defined as any lesion >or= 10mm in longest dimension on T1-weighted, gadolinium-enhanced MRI;
- •Prior treatment of brain metastases with WBRT and/or SRS;
- •Unequivocal evidence of new and / or progressive lesions in the brain on an imaging study;
- •Note: Subjects with progressive brain lesions are not required to meet RECIST
- •criteria for CNS progression in order to be eligible for this study.
- •Prior treatment with trastuzumab, either alone or in combination with chemotherapy is required. Trastuzumab will be discontinued at least 2 weeks prior to enrollment on study;
- •Cardiac ejection fraction within institutional range of normal as measured by echocardiogram. MUGA scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive;
- •At least 2 weeks since prior radiotherapy, last chemotherapy, immunotherapy, biologic therapy, or hormonal therapy for cancer, and sufficiently recovered or stabilized from side effects associated with prior therapy. Concurrent treatment with bisphosphonates is permitted;
- •Female subjects with child bearing potential or male subjects able to father a child must be completely abstinent from intercourse or use acceptable methods for birth control during the course of the study;
- •Subjects must have normal organ and marrow function as defined in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 188
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 56
排除标准
- •1. Subjects who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or who have unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment;
- •2. Concurrent treatment with an investigational agent or participation in another treatment clinical trial;
- •3. Subjects receiving concurrent chemotherapy, radiation therapy, immunotherapy, biologic therapy (including an ErbB1 and/or ErbB2 inhibitor), or hormonal therapy for treatment of their cancer. Hormone therapy for ovarian suppression which has
- •been used for > 6 months, during which time there has been disease progression in
- •the brain, is allowed. Concurrent treatment with bisphosphonates is allowed;
- •4. Subjects with leptomeningeal carcinomatosis as the only site of CNS involvement;
- •5. History of allergic reactions attributed to compounds of similar chemical
- •composition (quinazolines) to lapatinib;
- •6. Concurrent treatment with medications that are either inducers or inhibitors of CYP3A4 is prohibited. (For important exceptions, refer to Section 8.2, Prohibited Medications);
- •7. Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with active, uncontrolled ulcerative colitis are also excluded;
- •8. History of immediate or delayed hypersensitivity reaction to gadolinium contrast
- •agents, or other contraindication to gadolinium contrast;
- •9. Other known contraindication to MRI, such as a cardiac pacemaker, implanted cardiac defibrillator, brain aneurysm clips, cochlear implant, ocular foreign body, or shrapnel;
- •10. Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety;
- •11. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;
- •12. Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel, CNS vasculitis, or malignant hypertension;
- •13. Active cardiac disease, defined as one or more of the following:
- •? History of uncontrolled or symptomatic angina
- •? History of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation
- •? Myocardial infarction < 6 months from study entry
- •? Uncontrolled or symptomatic congestive heart failure
- •? Ejection fraction below the institutional normal limit
- •? Any other cardiac condition, which in the opinion of the treating physician,
- •would make this protocol unreasonably hazardous for the patient
- •14. Uncontrolled infection;
- •15. History of other malignancy, except for curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. Subjects with other malignancies who have been disease-free for at least 5 years are eligible;
- •16. Pregnant or lactating females.
研究者
相似试验
进行中（未招募）
1 期
A Phase II Study of Lapatinib for Brain Metastases in Subjectswith ErbB2-Positive Breast Cancer Following Trastuzumab basedSystemic Therapy and Cranial RadiotherapyProgressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.EUCTR2005-003944-68-GRGlaxoSmithKline R&D Ltd220
进行中（未招募）
1 期
A Phase II Study of Lapatinib for Brain Metastases in Subjectswith ErbB2-Positive Breast Cancer Following Trastuzumab basedSystemic Therapy and Cranial RadiotherapyProgressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.EUCTR2005-003944-68-BEGlaxoSmithKline R&D Ltd220
进行中（未招募）
1 期
A Study of Lapatinib for Brain Metastases in Subjects with ErbB2-PositiveBreast Cancer Following Trastuzumab Therapy and Cranial RadiotherapyEUCTR2005-003944-68-GBovartis Pharma Services AG220
进行中（未招募）
1 期
A Study of Lapatinib for Brain Metastases in Subjects with ErbB2-PositiveBreast Cancer Following Trastuzumab Therapy and Cranial RadiotherapyProgressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.EUCTR2005-003944-68-ATovartis Pharma Services AG220
进行中（未招募）
1 期
A Phase II Study of Lapatinib for Brain Metastases in Subjectswith ErbB2-Positive Breast Cancer Following Trastuzumab basedSystemic Therapy and Cranial RadiotherapyEstudio fase II de lapatinib en metástasis cerebrales en pacientes con cáncer de mama ErbB2 positivo tras tratamiento sistémico con terapia basada en trastuzumab y radioterapia craneal.Progressive symptomatic or asymptomatic ErbB2 overexpressing breast cancer brain metastases.Progresión sintomática o asintomática de metastasis cerebrales de cáncer de mama que sobreexpresa ErbB2EUCTR2005-003944-68-ESGlaxoSmithKline, S.A.220